1. A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. (22nd April 2016) Authors: Goy, Andre; Forero, Andres; Wagner‐Johnston, Nina; Christopher Ehmann, W.; Tsai, Michaela; Hatake, Kiyohiko; Ananthakrishnan, Revathi; Volkert, Angela; Vandendries, Erik; Ogura, Michinori Journal: British journal of haematology Issue: Volume 174:Number 4(2016) Page Start: 571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment. (22nd August 2019) Authors: Marks, David I.; van Oostrum, Ilse; Mueller, Sabrina; Welch, Verna; Vandendries, Erik; Loberiza, Fausto R.; Böhme, Sarah; Su, Yun; Stelljes, Matthias; Kantarjian, Hagop M. Journal: Cancer medicine Issue: Volume 8:Number 13(2019:Oct.) Page Start: 5959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATE. Issue 8 (30th January 2018) Authors: Jabbour, Elias J.; DeAngelo, Daniel J.; Stelljes, Matthias; Stock, Wendy; Liedtke, Michaela; Gökbuget, Nicola; O'Brien, Susan; Wang, Tao; Paccagnella, M. Luisa; Sleight, Barbara; Vandendries, Erik; Advani, Anjali S.; Kantarjian, Hagop M. Journal: Cancer Issue: Volume 124:Issue 8(2018) Page Start: 1722 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia. Issue 6 (24th November 2020) Authors: Stock, Wendy; Martinelli, Giovanni; Stelljes, Matthias; DeAngelo, Daniel J.; Gökbuget, Nicola; Advani, Anjali S.; O'Brien, Susan; Liedtke, Michaela; Merchant, Akil A.; Cassaday, Ryan D.; Wang, Tao; Zhang, Hui; Vandendries, Erik; Jabbour, Elias; Marks, David I.; Kantarjian, Hagop M. Journal: Cancer Issue: Volume 127:Issue 6(2021) Page Start: 905 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. (January 2020) Authors: Jabbour, Elias; Gökbuget, Nicola; Advani, Anjali; Stelljes, Matthias; Stock, Wendy; Liedtke, Michaela; Martinelli, Giovanni; O'Brien, Susan; Wang, Tao; Laird, A. Douglas; Vandendries, Erik; Neuhof, Alexander; Nguyen, Kevin; Dakappagari, Naveen; DeAngelo, Daniel J.; Kantarjian, Hagop Journal: Leukemia research Issue: Volume 88(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. (17th August 2020) Authors: Cassaday, Ryan D.; Marks, David I.; DeAngelo, Daniel J.; Jabbour, Elias J.; Advani, Anjali S.; O'Brien, Susan; Wang, Tao; Neuhof, Alexander; Vandendries, Erik; Kantarjian, Hagop M.; Stock, Wendy; Stelljes, Matthias Journal: British journal of haematology Issue: Volume 191:Number 3(2020) Page Start: e77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Issue 8 (2nd July 2020) Authors: Jabbour, Elias; Stelljes, Matthias; Advani, Anjali S.; DeAngelo, Daniel J.; Gökbuget, Nicola; Marks, David I.; Stock, Wendy; O'Brien, Susan; Cassaday, Ryan D.; Wang, Tao; Neuhof, Alexander; Vandendries, Erik; Kantarjian, Hagop Journal: Leukemia & lymphoma Issue: Volume 61:Issue 8(2020) Page Start: 2012 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study. Issue 14 (28th March 2019) Authors: Kantarjian, Hagop M.; DeAngelo, Daniel J.; Stelljes, Matthias; Liedtke, Michaela; Stock, Wendy; Gökbuget, Nicola; O'Brien, Susan M.; Jabbour, Elias; Wang, Tao; Liang White, Jane; Sleight, Barbara; Vandendries, Erik; Advani, Anjali S. Journal: Cancer Issue: Volume 125:Issue 14(2019) Page Start: 2474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin. Issue 5 (9th July 2019) Authors: Fostvedt, Luke K.; Hibma, Jennifer E.; Masters, Joanna C.; Vandendries, Erik; Ruiz‐Garcia, Ana Journal: Clinical pharmacology & therapeutics Issue: Volume 106:Issue 5(2019) Page Start: 1006 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. (1st January 2017) Authors: Sangha, Randeep; Davies, Andrew; Dang, Nam H.; Ogura, Michinori; MacDonald, David A.; Ananthakrishnan, Revathi; Paccagnella, M. Luisa; Vandendries, Erik; Boni, Joseph; Goh, Yeow Tee Journal: Journal of drug assessment Issue: Volume 6(2017) Page Start: 10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗